Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310060 | 0.83 | CYP11B1 (0.44) | CYP11B1CYP11B2CYP1A2CHRM1HRH3 | |
| SCHEMBL3309660 | 0.83 | KIF11 (0.45) | CYP11B1CYP11B2CYP1A2CHRM1BMPR1B | |
| SCHEMBL3312986 | 0.83 | HRH3 (0.47) | CYP11B1CYP11B2CYP1A2CHRM1BMPR1B | |
| SCHEMBL3307704 | 0.79 | MAPT (0.53) | CYP11B1CYP11B2CYP1A2BMPR1BBMPR1A | |
| SCHEMBL3599798 | 0.76 | ATAD2 (0.46) | CYP11B1CYP11B2CYP1A2CHRM1BMPR1B | |
| SCHEMBL3599801 | 0.76 | ATAD2 (0.68) | CYP11B1CYP11B2CYP1A2CHRM1ATAD2 | |
| SCHEMBL13386729 | 0.74 | ATAD2 (0.47) | CYP11B1CYP11B2CYP1A2CHRM1BMPR1B | |
| SCHEMBL3304919 | 0.73 | CYP1A2 (0.41) | CYP11B1CYP11B2CYP1A2CHRM1ATAD2 | |
| SCHEMBL3310040 | 0.73 | HDAC1 (0.43) | CYP11B1CYP11B2CYP1A2HDAC6HDAC1 | |
| SCHEMBL14277003 | 0.72 | POLB (0.61) | CHRM1CHRM2CHRM4CHRM5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | claimed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | claimed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | CYP11B1 1655/4885CYP11B2 1716/4885CYP1A2 2073/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | CYP11B1 1355/4885CYP11B2 1629/4885CYP1A2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.